IGF-1
Educational resource. Not medical advice. No dosing or instructions.
Safety grade
5/10
Moderate
Also known as
igf 1igf-1igf1insulin like growth factor 1insulin-like growth factor 1
AA sequence
Not available yet.
No overview has been added yet.
Why people are interested in this peptide and how it is commonly discussed in real-world wellness, rehabilitation, and athletic communities.
Why people are interested
- Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.
- general recovery and resilience interest (anecdotal)
- common biohacker curiosity due to community reports
- interest in mechanisms suggested by early evidence
- used in goal-based stacking discussions (anecdotal)
- exploration in wellness communities despite evidence limits
IGF-1 is a powerful growth factor with prescription uses in specific deficiencies. It is not a wellness peptide; misuse can carry serious risks, including metabolic and growth-related concerns.
Common reasons people consider it
- clinical use in rare IGF-1 deficiency contexts under specialist care
- physiology relevance in growth and metabolism signaling
- often discussed for muscle and recovery goals (high risk in non-medical use)
Most commonly reported downsides
- fluid retention
- joint pain
- headache
- fatigue
- blood sugar swings (including low blood sugar)
Rare but important symptoms to watch for
These are uncommon, but if they occur, stop and seek medical care.
- severe hypoglycemia symptoms (confusion, fainting, seizure)
- chest pain, severe shortness of breath, or collapse
- severe swelling or neurologic symptoms (urgent evaluation)
- severe allergic reaction symptoms (hives, facial swelling, trouble breathing)
Who should be cautious
- anyone without endocrinology supervision for a defined indication
- people with diabetes or unstable blood sugar control
- people with cancer history or active malignancy concern (growth signaling context)
- pregnant or breastfeeding individuals
- adolescents (growth-axis manipulation plus high consequence)
Interactions summarize known or plausible ways this peptide may intersect with medications, supplements, or physiologic states. Use this as a risk-awareness map: what to ask about, what to watch for, and what deserves a clinician conversation.
Medication classes
Supplement classes
None
Other peptides
None
Developmental risk is flagged due to limited adolescent data and uncertain long-term effects. Endocrine, growth, neurodevelopmental, and metabolic setpoints may be sensitive to perturbation. This section is descriptive only; uncertainty is explicitly acknowledged.
No curated human clinical sources have been added yet.
Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.
Pep-Talk is informational only and not medical advice. We make no warranties and are not liable for actions you take. You are responsible for your decisions and outcomes.
Community notes
Educational discussion only. No dosing, protocols, schedules, or instructions. Submissions are moderated before appearing.
Loading…
Submit a note